PT921125E - Derivados de 1,38-triaza-espiro 4,5 decan-4-ona - Google Patents

Derivados de 1,38-triaza-espiro 4,5 decan-4-ona

Info

Publication number
PT921125E
PT921125E PT98122511T PT98122511T PT921125E PT 921125 E PT921125 E PT 921125E PT 98122511 T PT98122511 T PT 98122511T PT 98122511 T PT98122511 T PT 98122511T PT 921125 E PT921125 E PT 921125E
Authority
PT
Portugal
Prior art keywords
espiro
triaza
decan
ona
derivatives
Prior art date
Application number
PT98122511T
Other languages
English (en)
Inventor
Geo Adam
Andrea Cesura
Guido Galley
Francois Jenck
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT921125E publication Critical patent/PT921125E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
PT98122511T 1997-12-05 1998-11-27 Derivados de 1,38-triaza-espiro 4,5 decan-4-ona PT921125E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
PT921125E true PT921125E (pt) 2002-06-28

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98122511T PT921125E (pt) 1997-12-05 1998-11-27 Derivados de 1,38-triaza-espiro 4,5 decan-4-ona

Country Status (29)

Country Link
US (1) US6043366A (pt)
JP (1) JP3366868B2 (pt)
KR (1) KR19990062800A (pt)
CN (1) CN1118467C (pt)
AR (1) AR016428A1 (pt)
AT (1) ATE212635T1 (pt)
AU (1) AU744338B2 (pt)
BR (1) BR9805297B1 (pt)
CA (1) CA2255171C (pt)
CO (1) CO4990965A1 (pt)
CZ (1) CZ399698A3 (pt)
DE (1) DE69803653T2 (pt)
DK (1) DK0921125T3 (pt)
ES (1) ES2170446T3 (pt)
HR (1) HRP980613A2 (pt)
HU (1) HUP9802807A3 (pt)
ID (1) ID21413A (pt)
IL (1) IL127399A0 (pt)
MA (1) MA26573A1 (pt)
NO (1) NO312161B1 (pt)
NZ (1) NZ333159A (pt)
PE (1) PE135299A1 (pt)
PL (1) PL330062A1 (pt)
PT (1) PT921125E (pt)
SG (1) SG71173A1 (pt)
TR (1) TR199802520A2 (pt)
TW (1) TW408123B (pt)
YU (1) YU55198A (pt)
ZA (1) ZA9811128B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP4356453B2 (ja) * 2001-07-23 2009-11-04 萬有製薬株式会社 ４−オキソイミダゾリジン−２−スピロピペリジン誘導体
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
RS20050208A (en) * 2002-09-09 2007-08-03 Janssen Pharmaceutica N.V., Hydroxy alkyl substituted 1,3,8- triazaspiro/4,5/decan-4- one derivatives useful for the treatment of orl-1 receptor mediated disorders
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20080287478A1 (en) * 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
JP5043825B2 (ja) * 2005-03-22 2012-10-10 エフ．ホフマン−ラ ロシュ アーゲー Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
WO2007149873A2 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
EA200970517A1 (ru) * 2006-11-28 2009-12-30 Янссен Фармацевтика Н.В. Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она
WO2008105497A1 (ja) 2007-03-01 2008-09-04 Mitsubishi Tanabe Pharma Corporation ベンゾイミダゾール化合物およびその医薬用途
WO2008124209A1 (en) * 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
EP2443124B1 (en) 2009-06-16 2014-01-22 Merck Sharp & Dohme Corp. Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones
EP3317279B1 (en) * 2015-07-03 2021-01-27 H. Hoffnabb-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS51100084A (pt) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
GR73633B (pt) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
US6043366A (en) 2000-03-28
ATE212635T1 (de) 2002-02-15
DE69803653D1 (de) 2002-03-14
TW408123B (en) 2000-10-11
AR016428A1 (es) 2001-07-04
YU55198A (sh) 2001-12-26
TR199802520A3 (tr) 1999-06-21
CA2255171C (en) 2009-09-29
ID21413A (id) 1999-06-10
BR9805297B1 (pt) 2010-07-13
NZ333159A (en) 2000-06-23
ES2170446T3 (es) 2002-08-01
CA2255171A1 (en) 1999-06-05
HUP9802807A3 (en) 2000-01-28
ZA9811128B (en) 1999-06-07
AU9608798A (en) 1999-06-24
CZ399698A3 (cs) 1999-06-16
HU9802807D0 (en) 1999-02-01
AU744338B2 (en) 2002-02-21
NO312161B1 (no) 2002-04-02
NO985684D0 (no) 1998-12-04
KR19990062800A (ko) 1999-07-26
JPH11228575A (ja) 1999-08-24
JP3366868B2 (ja) 2003-01-14
BR9805297A (pt) 2000-02-01
SG71173A1 (en) 2000-03-21
CO4990965A1 (es) 2000-12-26
PL330062A1 (en) 1999-06-07
NO985684L (no) 1999-06-07
IL127399A0 (en) 1999-10-28
DE69803653T2 (de) 2002-08-29
PE135299A1 (es) 2000-01-18
CN1222521A (zh) 1999-07-14
MA26573A1 (fr) 2004-12-20
HRP980613A2 (en) 1999-08-31
DK0921125T3 (da) 2002-05-13
CN1118467C (zh) 2003-08-20
HUP9802807A2 (hu) 1999-08-30
TR199802520A2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
PT1005446E (pt) Derivados de n-aroilfenilalanina
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
ATE340176T1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
DE69817186D1 (de) Diaminorhodamin-derivate
PT915088E (pt) Derivados de d-prolina
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
ATE255098T1 (de) Substituierte chromanderivate
PT1003719E (pt) Derivados microbicidas de n-sulfonil-glicinalquiniloxifenemetilamida
PT1027362E (pt) Derivados de cetolidos 2-halogeno-6-o-substituidos
FR2763953B1 (fr) Derives de 5'-desoxy-cytidine
ATE255099T1 (de) Substituierte chromanderivate
ATE292632T1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin- derivate
MA26480A1 (fr) Derives de phenoxymethylpiperidine
DE69828780D1 (de) Amidinocamptpthecin-derivate
PT1060183E (pt) Derivados de 5'-desoxicitidina
PT966437E (pt) Derivados de 5-aroilnaftaleno
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
ATE243218T1 (de) 2''-deoxyhygromycinderivate
MA26481A1 (fr) Derives d'arylsecocholadiene
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin